Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.3 · PDF-Seite 6
HOS-118621 · Präparat HOS-094855
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Severe renal impairment (CrCL < 30 mL/min) in adult patients
• eGFR < 50 mL/min/1.73 m2 in paediatric patients
• Active clinically significant bleeding
• Lesion or condition, if considered a significant risk factor for major bleeding. This may include
current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
6
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 58c4826e564b5c5b7f1abc93ec498be4215981e3fc8a5222c2a54f71816b01c4 · Zeichen 0–1751 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.3 · PDF-Seite 38–39
HOS-118701 · Präparat HOS-094855
38
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage ec2e999673d5b90adcb3018232692e9cba05e46844ff8f9fe74dad3d32d8172e · Zeichen 520–1753 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.3 · PDF-Seite 78–79
HOS-118789 · Präparat HOS-094855
78
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 30c550ec0ab8ef152af1fe03e09c53747fb57851a2196eef5c1b464bb4db5f2f · Zeichen 520–1753 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.3 · PDF-Seite 113–114
HOS-118875 · Präparat HOS-094855
113
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2) or when UFH is given at doses
necessary to maintain an open central venous or arterial catheter (see section 4.5).
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 308c96bdc025271910c30c2a89b1c7a62217151b0bbcfcdea4bed4d500b70ffb · Zeichen 551–1650 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-118657 · Präparat HOS-094855
NSAIDs NSAIDs given for short-term analgesia have been shown not to be associated with
increased bleeding risk when given in conjunction with dabigatran etexilate. With
chronic use in a phase III clinical trial comparing dabigatran to warfarin for stroke
prevention in atrial fibrillation patients (RE-LY), NSAIDs increased the risk of
bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Clopidogrel In young healthy male volunteers, the concomitant administration of dabigatran
etexilate and clopidogrel resulted in no further prolongation of capillary bleeding
times compared to clopidogrel monotherapy. In addition, dabigatran AUCτ,ss and
Cmax,ss and the coagulation measures for dabigatran effect or the inhibition of platelet
aggregation as measure of clopidogrel effect remained essentially unchanged
comparing combined treatment and the respective mono-treatments. With a loading
dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased
by about 30-40 % (see section 4.4).
ASA Co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase
the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA,
respectively (see section 4.4).
LMWH The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not
been specifically investigated. After switching from 3-day treatment of once daily
40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to
dabigatran was slightly lower than that after administration of dabigatran etexilate
(single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after
dabigatran etexilate administration with enoxaparin pre-treatment compared to that
after treatment with dabigatran etexilate alone. This is considered to be due to the
carry-over effect of enoxaparin treatment, and regarded as not clinically relevant.
Other dabigatran related anti-coagulation tests were not changed significantly by the
pre-treatment of enoxaparin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) clopidogrel (HOS-087927) enoxaparin (HOS-118623) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 0a19359480c6a0c248c94155bba1861177ff79423de391a6a6b273c2558ac642 · Zeichen 9052–11373 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 47
HOS-118729 · Präparat HOS-094855
NSAIDs NSAIDs given for short-term analgesia have been shown not to be associated with
increased bleeding risk when given in conjunction with dabigatran etexilate. With
chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by
approximately 50 % on both dabigatran etexilate and warfarin.
Clopidogrel In young healthy male volunteers, the concomitant administration of dabigatran
etexilate and clopidogrel resulted in no further prolongation of capillary bleeding
times compared to clopidogrel monotherapy. In addition, dabigatran AUCτ,ss and
Cmax,ss and the coagulation measures for dabigatran effect or the inhibition of platelet
aggregation as measure of clopidogrel effect remained essentially unchanged
comparing combined treatment and the respective mono-treatments. With a loading
dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased
by about 30-40 % (see section 4.4).
ASA Co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase
the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA,
respectively (see section 4.4).
LMWH The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not
been specifically investigated. After switching from 3-day treatment of once daily
40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to
dabigatran was slightly lower than that after administration of dabigatran etexilate
(single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after
dabigatran etexilate administration with enoxaparin pre-treatment compared to that
after treatment with dabigatran etexilate alone. This is considered to be due to the
carry-over effect of enoxaparin treatment, and regarded as not clinically relevant.
Other dabigatran related anti-coagulation tests were not changed significantly by the
pre-treatment of enoxaparin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) clopidogrel (HOS-087927) enoxaparin (HOS-118623) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage b16582f09931d42ccce17c0b2c6b34ef526c7eb07f284be66b7d33a46c1635de · Zeichen 9552–11754 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 87
HOS-118818 · Präparat HOS-094855
NSAIDs NSAIDs given for short-term analgesia have been shown not to be associated with
increased bleeding risk when given in conjunction with dabigatran etexilate. With
chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by
approximately 50 % on both dabigatran etexilate and warfarin.
Clopidogrel In young healthy male volunteers, the concomitant administration of dabigatran
etexilate and clopidogrel resulted in no further prolongation of capillary bleeding
times compared to clopidogrel monotherapy. In addition, dabigatran AUCτ,ss and
Cmax,ss and the coagulation measures for dabigatran effect or the inhibition of platelet
aggregation as measure of clopidogrel effect remained essentially unchanged
comparing combined treatment and the respective mono-treatments. With a loading
dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased
by about 30-40 % (see section 4.4).
ASA Co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase
the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA,
respectively (see section 4.4).
LMWH The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not
been specifically investigated. After switching from 3-day treatment of once daily
40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to
dabigatran was slightly lower than that after administration of dabigatran etexilate
(single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after
dabigatran etexilate administration with enoxaparin pre-treatment compared to that
after treatment with dabigatran etexilate alone. This is considered to be due to the
carry-over effect of enoxaparin treatment, and regarded as not clinically relevant.
Other dabigatran related anti-coagulation tests were not changed significantly by the
pre-treatment of enoxaparin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) clopidogrel (HOS-087927) enoxaparin (HOS-118623) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage b16582f09931d42ccce17c0b2c6b34ef526c7eb07f284be66b7d33a46c1635de · Zeichen 9563–11765 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 120
HOS-118904 · Präparat HOS-094855
NSAIDs NSAIDs given for short-term analgesia have been shown not to be associated with
increased bleeding risk when given in conjunction with dabigatran etexilate. With
chronic use in a phase III clinical trial comparing dabigatran to warfarin for stroke
prevention in atrial fibrillation patients (RE-LY), NSAIDs increased the risk of
bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Clopidogrel In young healthy male volunteers, the concomitant administration of dabigatran
etexilate and clopidogrel resulted in no further prolongation of capillary bleeding
times compared to clopidogrel monotherapy. In addition, dabigatran AUCτ,ss and
Cmax,ss and the coagulation measures for dabigatran effect or the inhibition of platelet
aggregation as measure of clopidogrel effect remained essentially unchanged
comparing combined treatment and the respective mono-treatments. With a loading
dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased
by about 30-40 % (see section 4.4).
ASA Co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase
the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA,
respectively (see section 4.4).
LMWH The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not
been specifically investigated. After switching from 3-day treatment of once daily
40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to
dabigatran was slightly lower than that after administration of dabigatran etexilate
(single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after
dabigatran etexilate administration with enoxaparin pre-treatment compared to that
after treatment with dabigatran etexilate alone. This is considered to be due to the
carry-over effect of enoxaparin treatment, and regarded as not clinically relevant.
Other dabigatran related anti-coagulation tests were not changed significantly by the
pre-treatment of enoxaparin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) clopidogrel (HOS-087927) enoxaparin (HOS-118623) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 0a19359480c6a0c248c94155bba1861177ff79423de391a6a6b273c2558ac642 · Zeichen 9055–11376 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-120038 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 595–1059 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 32
HOS-120072 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 652–1116 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 58
HOS-120102 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 595–1059 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 90
HOS-120134 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 595–1059 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 121
HOS-120166 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 651–1115 im Abschnitt
Gegenanzeigen · Xarelto
Xarelto 1 mg/mL granules for oral suspension · Abschnitt 4.3 · PDF-Seite 145
HOS-120197 · Präparat HOS-095079
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral
anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of
switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain
an open central venous or arterial catheter (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3456e42889d183a7a9ca6e80ade85a3bd1999a02df3c6a197e67f57763c81981 · Zeichen 595–1059 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-120048 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2520–2969 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-120081 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2576–3025 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62
HOS-120112 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2800–3249 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94
HOS-120144 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2800–3249 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 124
HOS-120175 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2578–3027 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 1 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 149
HOS-120206 · Präparat HOS-095079
Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single
dose) an additive effect on anti-factor Xa activity was observed without any additional effects on
clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.
Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any
other anticoagulants (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxaparin (HOS-118623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 600fb693d2d234df8351bc3e626022ab3bdc77305e3ebf7e18a24356e720b700 · Zeichen 2800–3249 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.